Evaluation of impact of steroid replacement treatment on bone health in children with 21-hydroxylase deficiency
Abstract
Abstract There are conflicting data regarding the potential impact of chronic glucocorticoid (GC) therapy on the bone mineral density of patients with congenital adrenal hyperplasia (CAH). Previous studies performed by dual-energy X-ray absorptiometry reported conflicting results. The purpose of this study was to assess the impact of chronic GC replacement treatment in children with classical and non classical CAH due to 21-hydroxylase deficiency (21-OHD) by quantitative ultrasonometry (QUS), an easy, cheap, and radiation-free technique. The study population consisted of nineteen 21-OHD patients (nine males) on lifelong GC treatment. Anthropometric, hormonal, and treatment data were recorded for each patient, and bone quality was assessed by QUS measurements. QUS findings (amplitude-dependent speed of sound and bone transmission time) were normal in 21-OHD patients and did not correlate with duration of treatment, daily, total, and yearly hydrocortisone dose. Furthermore, no significant correlation was found between QUS findings and 17α-hydroxy progesterone, Δ4-androstenedione, and testosterone levels. In conclusion, our results provide reassurance that currently used replacement doses of GC do not have a major impact on bone in patients with CAH. QUS seems to be a reliable tool for screening of bone health in children with 21-OHD
Autore Pugliese
Tutti gli autori
-
VENTURA A.;LONERO A.;BRUNETTI G.;CAVALLO L.;GRANO M.;FAIENZA M.F.;GIORDANO P.
Titolo volume/Rivista
Non Disponibile
Anno di pubblicazione
2015
ISSN
1355-008X
ISBN
Non Disponibile
Numero di citazioni Wos
1
Ultimo Aggiornamento Citazioni
Non Disponibile
Numero di citazioni Scopus
2
Ultimo Aggiornamento Citazioni
Non Disponibile
Settori ERC
Non Disponibile
Codici ASJC
Non Disponibile
Condividi questo sito sui social